Nine of the largest pharma companies ink deals with Trump to lower drug prices
The agreements reduce prices on drugs that treat numerous costly and chronic conditions.
The agreements reduce prices on drugs that treat numerous costly and chronic conditions.
The company has committed more than $70 billion in U.S. investments to boost domestic production and innovation.
Google Trends analysis revealed that new types of health-related searches emerged in the second half of 2025 and will continue into next year.
The Council for Responsible Nutrition announced its 2026 Board of Directors as it gears up for increased regulation and legislation.
The end of enhanced ACA premium support in 2026 will likely push millions off marketplace plans, increasing uninsured visits to safety-net clinics and assistance programs.
APhA believes that moving marijuana to Schedule III will help accelerate research into its medicinal applications and potentially lead to safer and more effective therapeutic uses.
Grocer helps families unwrap hope and nourishment through community-powered giving campaigns.
CHPA said the bill would boost OTC market innovation by clarifying and standardizing the review process for new and updated self-care products.
“The FDA submission of CagriSema marks an important milestone and signals a new era in weight management,” said Novo Nordisk CEO.
“The CPI numbers released today underscore the continued challenges grocery shoppers must navigate to get the most out of their grocery dollar. Nevertheless, they remain resilient and savvy in the face of these challenges."
Retailer surprises customers across the Midwest with shopping sprees just in time for the holidays.
Nationwide campaign highlights the quality, value, and variety of store brand products helping shoppers stretch their budgets year-round.
Closeout retailer brings holiday joy to families in need at Christmas.
Today’s MPC letter said there is no need to wait for court action or for new data.
Dr. Eduardo Alfonso and Steven Collis are joining their board of directors.
Meaningful reform must address three key issues: transparency, fair pharmacy reimbursement, and ending PBM spread pricing.